MedTrace Logo

Vasopressin and Methylprednisolone for In-Hospital Cardiac Arrest

NCT03640949 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 501

Last updated 2022-03-02

Study results available
· View outcomes & findings →

Summary

This is an investigator-initiated, multicenter, randomized, placebo-controlled, parallel group, double-blind, superiority trial of vasopressin and methylprednisolone during adult in-hospital cardiac arrest. There will be ten enrolling sites in Denmark. 492 adult patients with in-hospital cardiac arrest receiving at least one dose of adrenaline will be enrolled. The primary outcome is return of spontaneous circulation and key secondary outcomes include survival at 30 days and survival at 30 days with a favorable neurological outcome.

Conditions

  • Heart Arrest

Interventions

DRUG

Vasopressin, Arginine

20 IE of vasopressin per dose for a maximum of four doses (80 IU)

DRUG

Methylprednisolone

40 mg methylprednisolone once

DRUG

NaCl

Placebo

Sponsors & Collaborators

  • University of Aarhus

    collaborator OTHER

  • Lars Wiuff Andersen

    lead OTHER

Principal Investigators

  • Lars W Andersen, MD, MPH, PhD, DMSc · Aarhus University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-09-17
Primary Completion
2021-01-21
Completion
2022-01-21

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03640949 on ClinicalTrials.gov